July 19, 2017
Sponsored by
Philips Genomics

Validation, Then Discovery: Establishing Truth from cfDNA Genotyping of Lung Cancer


Assistant Professor of Medicine, Dana-Farber Cancer Institute, Harvard Medical School

Chief Technology Officer, Philips Genomics 

This webinar provides an overview of how liquid biopsies can be integrated into lung cancer care.

Genotyping of plasma cell-free DNA is rapidly changing the management approach for genotype-defined lung cancers. Widely available assays now have the ability to noninvasively identify driver mutations in cfDNA, monitor response to therapy, and characterize emerging resistance. However, such liquid biopsies also have clear limitations and existing assays are unlikely to replace tumor biopsies completely.

In this webinar, Geoffrey Oxnard of Dana-Farber Cancer Institute discusses an optimal approach for integrating liquid biopsies into lung cancer care, while also providing his outlook on how liquid biopsies may become a routine part of lung cancer treatment in the years ahead. 

Dr. Dimitrova discusses how the Philips IntelliSpace Genomics platform brings data from liquid biopsies (and other NGS tests) alongside disease histology and patient phenotype for a complete clinical picture for clinical decision making.

Sponsored by

CNBC reports that Amazon invested in the startup Grail as it sees an opportunity for its cloud computing company in genomics.

Lawrence Krauss writes at Slate that science is needed for good public policy and should not be ignored.

Researchers are working on re-making the yeast genome from scratch, according to the Associated Press.

In Cell this week: functional profiling of Plasmodium genome, a self-inactivating rabies virus, and more.

Sponsored by

This webinar will demonstrate a new approach that combines precise FFPE tumor isolation with extraction-free DNA/RNA library preparation to minimize material losses and reduce the amount of tissue input required for NGS analysis.